MeSH tree: D27.505.954.427.700
Using psychedelics to treat psychiatric diseases has become less controversial as scientists continue to reveal their underlying mechanisms. In an eNeuro paper, researchers led by Pavel Ortinski, from the University of Kentucky, ...
Oct 27, 2025
0
13
Certain antidepressants can help alleviate chronic jaw pain caused by temporomandibular disorders (TMDs), according to a research review by a team of researchers with expertise in dentistry and pharmacy published in the Journal ...
Oct 23, 2025
0
12
Researchers explored how women experience menopause care within the NHS, focusing on inequalities shaped by ethnicity, socioeconomic status and cultural norms.
Oct 22, 2025
0
8
Antidepressants can differ widely in how they physically affect the body, including around a 4 kg difference in weight change between certain drugs (approximately 2.5 kg weight loss from agomelatine and 2 kg weight gain from ...
Oct 21, 2025
0
28
People who are female, younger, more educated and have reported suicidal ideation are more likely to go to therapy or use psychiatric medications, according to Rutgers Health researchers.
Oct 14, 2025
0
10
Immersive virtual reality experiences can reproduce visual hallucination effects, miming those induced by the use of psychedelic substances.
Oct 9, 2025
0
39
The most basic assumption about how psychedelic medicine works is at least partially flawed: Psychedelics are altering not just a few specific brain cells, but the vast majority of them, according to a new University of Michigan ...
Sep 29, 2025
0
40
A new study led by Mass General Brigham investigators compared the effects of repeated intravenous (IV) ketamine and intranasal (IN) esketamine in patients with treatment-resistant depression. In a retrospective analysis ...
Sep 25, 2025
0
15
New machine learning models developed by University of South Australia (UniSA) researchers could help clinicians identify when patients can successfully stop long-term antidepressant use.
Sep 24, 2025
0
23
FDA leaders under President Donald Trump are moving to abandon a decades-old policy of asking outside experts to review drug applications, a move critics say would shield the agency's decisions from public scrutiny.
Sep 15, 2025
0
12
